Efficacy and Safety of Rupatadine 10 and 20 Mg in Chronic Idiopathic Urticaria

NCT00199251 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2005-12-23

No results posted yet for this study

Summary

· To evaluate the efficacy of rupatadine 10 and 20 mg for the treatment of CIU symptoms over four-week treatment period in comparison with placebo.

Conditions

  • Urticaria

Interventions

DRUG

RUPATADINE

Sponsors & Collaborators

  • J. Uriach and Company

    lead INDUSTRY

Principal Investigators

  • EVA ARNAIZ, PhD · J. Uriach y Compañía

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Completion
2005-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00199251 on ClinicalTrials.gov